Fannie Mae, Freddie Mac shares tumble after conservatorship comments
LONDON - Autolus Therapeutics ’ (NASDAQ:AUTL) obecabtagene autoleucel (obe-cel) demonstrated sustained remission in adult patients with relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL), according to updated data presented at the European Hematology Association Congress.
After approximately three years of follow-up in the FELIX study, the median duration of response reached 42.6 months, with 38% of responding patients maintaining remission without requiring any subsequent therapy by month 33. More than half of the patients remained in remission at the 24-month mark.
The data showed no new safety signals or Grade 3 or higher secondary malignancies during the extended follow-up period. The treatment demonstrated efficacy regardless of patient age, with deep and durable remissions observed in both younger (<55 years) and older (≥55 years) patient groups.
"These results suggest that obe-cel may be a definitive treatment for some patients with r/r B-ALL," according to the presentation. Factors associated with achieving higher remission rates included Philadelphia chromosome-positive disease, earlier obe-cel use, and relapsed disease status.
Additional findings indicated that lower disease burden at lymphodepletion and ongoing CAR T-cell persistence were independent factors linked to long-term remission and survival.
The company also presented data suggesting that the ALL-Hematotox model may better predict response, survival, and safety outcomes in adult patients with r/r B-ALL treated with obe-cel compared to the CAR-Hematotox model.
The information is based on a press release statement from Syncona Limited, a major investor in Autolus Therapeutics.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.